Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwidee for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229–263. https://doi.org/10.3322/caac.21834

Article  PubMed  Google Scholar 

Fang Y, Yu A, Ye L, Zhai G (2021) Research progress in tumor targeted immunotherapy. Expert Opin Drug Deliv 18(8):1067–1090. https://doi.org/10.1080/17425247.2021.1882992

Article  CAS  PubMed  Google Scholar 

Rui R, Zhou L, He S (2023) Cancer immunotherapies: advances and bottlenecks. Front Immunol 14:1212476. https://doi.org/10.3389/fimmu.2023.1212476

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen DS, Mellman I (2017) Elements of cancer immunity and the cancer-immune set point. Nature 541(7637):321–330. https://doi.org/10.1038/nature21349

Article  CAS  PubMed  Google Scholar 

Ghosh C, Luong G, Sun Y (2021) A snapshot of the PD-1/PD-L1 pathway. J Cancer 12(9):2735–2746. https://doi.org/10.7150/jca.57334

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li X, Zeng Q, Xu F, Jiang Y, Jiang Z (2023) Progress in programmed cell death-1/programmed cell death-ligand 1 pathway inhibitors and binding mode analysis. Mol Divers 27(4):1935–1955. https://doi.org/10.1007/s11030-022-10509-2

Article  CAS  PubMed  Google Scholar 

Wang T, Wu X, Guo C, Zhang K, Xu J, Li Z, Jiang S (2019) Development of inhibitors of the programmed cell Death-1/Programmed cell Death-Ligand 1 signaling pathway. J Med Chem 62(4):1715–1730. https://doi.org/10.1021/acs.jmedchem.8b00990

Article  CAS  PubMed  Google Scholar 

Wang F, Fu K, Wang Y, Pan C, Wang X, Liu Z, Yang C, Zheng Y, Li X, Lu Y, To KKW, Xia C, Zhang J, Shi Z, Hu Z, Huang M, Fu L (2024) Small-molecule agents for cancer immunotherapy. Acta Pharm Sinica B 14(3):905–952. https://doi.org/10.1016/j.apsb.2023.12.010

Article  CAS  Google Scholar 

Wu Q, Jiang L, Li SC, He QJ, Yang B, Cao J (2021) Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway. Acta Pharmacol Sin 42(1):1–9. https://doi.org/10.1038/s41401-020-0366-x

Article  CAS  PubMed  Google Scholar 

Boisgerault N, Bertrand P (2023) Inside PD-1/PD-L1,2 with their inhibitors. Eur J Med Chem 256:115465. https://doi.org/10.1016/j.ejmech.2023.115465

Article  CAS  PubMed  Google Scholar 

Chen R, Yuan D, Ma J (2022) Advances of biphenyl small-molecule inhibitors targeting PD-1/PD-L1 interaction in cancer immunotherapy. Future Med Chem 14(2):97–113. https://doi.org/10.4155/fmc-2021-0256

Article  CAS  PubMed  Google Scholar 

Ma J, Huang K, Ni X, Chen R, Xu B, Wang C (2019) Design, synthesis, biological activity and molecular Docking study of coumarin derivatives bearing 2-Methylbiphenyl moiety. Chem Res Chin Univ 35:410–417. https://doi.org/10.1007/s40242-019-8310-7

Article  CAS  Google Scholar 

Wang Y, Kun Huang, Gao Y, Yuan D, Ling L, Liu J, Wu S, Chen R, Li H, Xiong Y, Liu H, Ma J (2022) Discovery of Quinazoline derivatives as novel small-molecule inhibitors targeting the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) interaction. Eur J Med Chem 229:113998. https://doi.org/10.1016/j.ejmech.2021.113998

Article  CAS  PubMed  Google Scholar 

Wu X, Li H, Liu H, Ding X, Chen X, Yin C, Gao Y, Ma J (2024) Design, synthesis, and evaluation of 8-(o-Tolyl)quinazoline derivatives as Small-Molecule PD-1/PD-L1 antagonists. ACS Med Chem Lett 15(4):518–523. https://doi.org/10.1021/acsmedchemlett.4c00014

Article  CAS  PubMed  PubMed Central  Google Scholar 

Qin M, Cao Q, Zheng S, Tian Y, Zhang H, Xie J, Xie H, Liu Y, Zhao Y, Gong P (2019) Discovery of [1,2,4]Triazolo[4,3- a]pyridines as potent inhibitors targeting the programmed cell Death-1/Programmed cell Death-Ligand 1 interaction. J Med Chem 62(9):4703–4715. https://doi.org/10.1021/acs.jmedchem.9b00312

Article  CAS  PubMed  Google Scholar 

Wang T, Cai S, Wang M, Zhang W, Zhang K, Chen D, Li Z, Jiang S (2021) Novel biphenyl pyridines as potent Small-Molecule inhibitors targeting the programmed cell Death-1/Programmed cell Death-Ligand 1 interaction. J Med Chem 64(11):7390–7403. https://doi.org/10.1021/acs.jmedchem.1c00010

Article  CAS  PubMed  Google Scholar 

Huang K, Ma J (2023) Design, synthesis, PD-1/PD-L1 inhibitory activity screening and molecular Docking study of biphenyl compounds bearing triazine structure. J Liaocheng Univ (Natural Sci Edition) 36(4):82–92. https://link.cnki.net/doi/https://doi.org/10.19728/j.issn1672-6634.2023020013

Article  CAS  Google Scholar 

Muszak D, Surmiak E, Plewka J, Magiera-Mularz K, Kocik-Krol J, Musielak B, Sala D, Kitel R, Stec M, Weglarczyk K, Siedlar M, Dömling A, Skalniak L, Holak TA (2021) Terphenyl-Based Small-Molecule inhibitors of programmed cell Death-1/Programmed Death-Ligand 1 Protein-Protein interaction. J Med Chem 64(15):11614–11636. https://doi.org/10.1021/acs.jmedchem.1c00957

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu Y, Du H, Guo W, Liu B, Yan W, Zhang C, Qin L, Huang J, Wang H, Wu S, Ren W, Zou Y, Wang J, Zhu Q, Xu Y, Gu H (2024) Discovery of highly potent Small-Molecule PD-1/PD-L1 inhibitors with a novel scaffold for Cancer immunotherapy. J Med Chem 67(5):4083–4099. https://doi.org/10.1021/acs.jmedchem.3c02362

Article  CAS  PubMed  Google Scholar 

Wang K, Zhang X, Cheng Y, Qi Z, Ye K, Zhang K, Jiang S, Liu Y, Xiao Y, Wang T (2023) Discovery of novel PD-L1 inhibitors that induce the dimerization, internalization, and degradation of PD-L1 based on the fragment coupling strategy. J Med Chem 66(24):16807–16827. https://doi.org/10.1021/acs.jmedchem.3c01534

Article  CAS  PubMed  Google Scholar 

Tang K, Wang S, Gao W, Song Y, Yu B (2022) Harnessing the cyclization strategy for new drug discovery. Acta Pharm Sin B 12(12):4309–4326. https://doi.org/10.1016/j.apsb.2022.09.022

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li C, Su M, Zhu W, Kan W, Ge T, Xu G, Wang S, Sheng L, Gao F, Ye Y, Wang J, Zhou Y, Li J, Liu H (2022) Structure-Activity relationship study of Indolin-5-yl-cyclopropanamine derivatives as selective lysine specific demethylase 1 (LSD1) inhibitors. J Med Chem 65(5):4335–4349. https://doi.org/10.1021/acs.jmedchem.1c02156

Article  CAS  PubMed  Google Scholar 

Cho H, Shin I, Yoon H, Jeon E, Lee J, Kim Y, Ryu S, Song C, Kwon NH, Moon Y, Kim S, Kim ND, Choi HG, Sim T (2021) Identification of Thieno[3,2-d]pyrimidine derivatives as dual inhibitors of focal adhesion kinase and FMS-like tyrosine kinase 3. J Med Chem 64(16):11934–11957. https://doi.org/10.1021/acs.jmedchem.1c00459

Article  CAS  PubMed  Google Scholar 

Yang K, Li S, Wang T, Yan X, He Q, Ning R, Xu X, Yao W, Zhang X, Yang C, Jiang M, Deng L (2022) Development of an orally active Small-Molecule inhibitor of receptor activator of nuclear Factor-κB ligand. J Med Chem 65(16):10992–11009. https://doi.org/10.1021/acs.jmedchem.2c00081

Article  CAS  PubMed  Google Scholar 

Guo J, Luo L, Wang Z, Hu N, Wang W, Xie F, Liang E, Yan X, Xiao J, Li S (2022) Design, synthesis, and biological evaluation of linear aliphatic Amine-Linked triaryl derivatives as potent Small-Molecule inhibitors of the programmed cell Death-1/Programmed cell Death-Ligand 1 interaction with promising antitumor effects in vivo. J Med Chem 63(22):13825–13850. https://doi.org/10.1021/acs.jmedchem.0c01329

Article  CAS  Google Scholar 

Zhang H, Zhou S, Plewka J, Wu C, Zhu M, Yu Q, Musielak B, Wang X, Awadasseid A, Magiera-Mularz K et al (2023) Design, synthesis, and antitumor activity evaluation of 2-Arylmethoxy-4-(2,2′-dihalogen-substituted biphenyl-3-ylmethoxy) benzylamine derivatives as potent PD-1/PD-L1 inhibitors. J Med Chem 66(15):10579–10603. https://doi.org/10.1021/acs.jmedchem.3c00731

Article  CAS  PubMed